☰

Bryan D. Smith - Publications

Affiliations: 
2006 Department of Biochemistry University of Wisconsin, Madison, Madison, WI 
Tree Info Similar researchers PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Caldwell TM, Mi Ahn Y, Bulfer SL, Leary CB, Hood MM, Lu WP, Vogeti L, Vogeti S, Kaufman MD, Wise SC, Le Bourdonnec B, Smith BD, Flynn DL. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 128928. PMID 35961460 DOI: 10.1016/j.bmcl.2022.128928  0.312
2021 Smith BD, Kaufman MD, Wise SC, Ahn YM, Caldwell TM, Leary CB, Lu WP, Tan G, Vogeti L, Vogeti S, Wilky BA, Davis LE, Sharma M, Ruiz-Soto R, Flynn DL. Vimseltinib: A precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Molecular Cancer Therapeutics. PMID 34433663 DOI: 10.1158/1535-7163.MCT-21-0361  0.333
2021 Gupta A, Singh J, García-Valverde A, Serrano C, Flynn DL, Smith BD. Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GIST and Systemic Mastocytosis. Molecular Cancer Therapeutics. PMID 33947686 DOI: 10.1158/1535-7163.MCT-20-0824  0.377
2020 Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology. 3: 776. PMID 33328556 DOI: 10.1038/s42003-020-01508-w  0.347
2019 Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 35: 738-751.e9. PMID 31085175 DOI: 10.1016/J.Ccell.2019.04.006  0.772
2019 Smith BD, Vogeti L, Gupta A, Singh J, Al-Ani G, Bulfer SL, Caldwell TM, Timson MJ, Vogeti S, Ahn YM, Al-Hashimi H, Crawley CK, Heiniger CL, Leary CB, Proto JT, et al. Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B129  0.463
2018 Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman, Leary CB, Lu WP, Al-Ani G, Chen X, Entenberg D, Oktay MH, Wang Y, et al. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Molecular Cancer Therapeutics. 16: 2486-2501. DOI: 10.2210/Pdb6Mwe/Pdb  0.33
2018 Smith BD, Kaufman MD, Gupta A, Leary CB, Lu W, Bulfer SL, Al-Ani G, Singh J, Vogeti S, Heinrich MC, Flynn DL. Abstract 3925: Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618 Cancer Research. 78: 3925-3925. DOI: 10.1158/1538-7445.Am2018-3925  0.533
2017 Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman MD, Leary CB, Lu WP, Al-Ani G, Chen X, Entenberg D, Oktay MH, Wang Y, et al. The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors. Molecular Cancer Therapeutics. PMID 28838996 DOI: 10.1158/1535-7163.Mct-17-0241  0.385
2017 Janku F, Abdul Razak AR, Gordon MS, Brooks DG, Flynn DL, Kaufman M, Pitman J, Smith BD, Somaiah N, De Groot JF, Chen G, Jennings J, Salah S, Westwood D, Gerstenberger E, et al. Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. Journal of Clinical Oncology. 35: 2515-2515. DOI: 10.1200/Jco.2017.35.15_Suppl.2515  0.383
2016 Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, et al. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. PMID 27927766 DOI: 10.3324/Haematol.2016.152710  0.731
2016 Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro-Oncology. PMID 26965451 DOI: 10.1093/Neuonc/Now030  0.357
2016 Smith BD, Leary CB, Lu W, Kaufman MD, Flynn DL. Abstract 4889: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models Cancer Research. 76: 4889-4889. DOI: 10.1158/1538-7445.Am2016-4889  0.454
2016 Surriga O, Smith BD, Ambrosini G, Flynn DL, Carvajal RD, Schwartz GK. Abstract 4120: c-Met inhibition blocks MEK-induced tumor cell invasion in uveal melanoma Cancer Research. 76: 4120-4120. DOI: 10.1158/1538-7445.Am2016-4120  0.443
2015 Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutloski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell. PMID 26343583 DOI: 10.1016/J.Ccell.2015.08.002  0.493
2015 Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Molecular Cancer Therapeutics. 14: 2023-34. PMID 26285778 DOI: 10.1158/1535-7163.Mct-14-1105  0.751
2015 Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. Journal of Medicinal Chemistry. 58: 4165-79. PMID 25965804 DOI: 10.1021/Acs.Jmedchem.5B00067  0.753
2015 Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene. 34: 144-53. PMID 24362531 DOI: 10.1038/Onc.2013.539  0.379
2015 Flynn DL, Kaufman MD, Leary CB, Hood MM, Lu W, Turner BA, Wise SC, Rudoltz MS, Smith BD. Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-Pr01  0.404
2015 Smith BD, Kaufman MD, Leary CB, Hood MM, Lu W, Turner BA, Vogeti S, Wise SC, Flynn DL. Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A53  0.439
2015 Smith BD, Leary CB, Turner BA, Kaufman MD, Wise SC, Garcia-Rendueles MER, Fagin JA, Flynn DL. Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models Cancer Research. 75: 790-790. DOI: 10.1158/1538-7445.Am2015-790  0.476
2015 Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian B, Smith BD, Pollard JW, Jones JG, Flynn DL, Condeelis JS. Abstract 5125: Imaging the tumor microenvironment of metastasis reveals the mechanism of transient blood vessel permeability and tumor cell intravasation Cancer Research. 75: 5125-5125. DOI: 10.1158/1538-7445.Am2015-5125  0.351
2015 Harney A, Pignatelli J, Leung E, Oktay M, Wang Y, Smith BD, Flynn DL, Condeelis JS. Abstract 397: Rebastinib potently inhibits function of perivascular TIE2 expressing macrophagesin vitroandin vivo Cancer Research. 75: 397-397. DOI: 10.1158/1538-7445.Am2015-397  0.432
2015 Smith BD, Hood MM, Wise SC, Kaufman MD, Lu W, Rutkoski T, Flynn DL, Heinrich MC. Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models Cancer Research. 75: 2690-2690. DOI: 10.1158/1538-7445.Am2015-2690  0.759
2014 Peng S, Henry J, Kaufman M, Lu W, Smith BD, Vogeti S, Wise S, Zhang Y, Horn RV, Zhang X, Yin T, Yadav V, Huber L, Kays L, Walgren J, et al. Abstract DDT02-02: Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ddt02-02  0.514
2013 Smith BD, Hood MM, Kaufman MD, Berger M, Flynn DL, Wise SC. Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B78  0.404
2011 Smith BD, Higgin JJ, Raines RT. Site-specific folate conjugation to a cytotoxic protein. Bioorganic & Medicinal Chemistry Letters. 21: 5029-32. PMID 21570289 DOI: 10.1016/J.Bmcl.2011.04.081  0.729
2011 Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.Can-10-3224  0.473
2011 Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 19: 556-68. PMID 21481795 DOI: 10.1016/J.Ccr.2011.03.003  0.766
2011 Thiyagarajan N, Smith BD, Raines RT, Acharya KR. Functional and structural analyses of N-acylsulfonamide-linked dinucleoside inhibitors of RNase A. The Febs Journal. 278: 541-9. PMID 21205197 DOI: 10.1111/J.1742-4658.2010.07976.X  0.483
2011 Wise SC, Hood MM, Smith BD, Lister D, Lu W, Kaufman MD, McConville P, Flynn DL. Abstract 3594: Conformational control of FMS kinase for treatment of human malignancies Cancer Research. 71: 3594-3594. DOI: 10.1158/1538-7445.Am2011-3594  0.447
2010 Ahn YM, Clare M, Ensinger CL, Hood MM, Lord JW, Lu WP, Miller DF, Patt WC, Smith BD, Vogeti L, Kaufman MD, Petillo PA, Wise SC, Abendroth J, Chun L, et al. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic & Medicinal Chemistry Letters. 20: 5793-8. PMID 20800479 DOI: 10.1016/J.Bmcl.2010.07.134  0.381
2010 Heinrich MC, Wise S, Hood M, Smith B, Kaufman M, Lu W, Wang Y, Griffith D, Flynn D, Fletcher JA. In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors. Journal of Clinical Oncology. 28: 10007-10007. DOI: 10.1200/Jco.2010.28.15_Suppl.10007  0.486
2010 Wise SC, Smith BD, Hood MM, Kaufman MD, Lu W, Flynn DL. Abstract LB-300: Small molecule modulators of MET kinase for treatment of human malignancies Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-300  0.488
2008 Smith BD, Raines RT. Genetic selection for peptide inhibitors of angiogenin. Protein Engineering, Design & Selection : Peds. 21: 289-94. PMID 18308863 DOI: 10.1093/Protein/Gzm089  0.537
2006 Smith BD, Raines RT. Genetic selection for critical residues in ribonucleases. Journal of Molecular Biology. 362: 459-78. PMID 16920150 DOI: 10.1016/J.Jmb.2006.07.020  0.505
2005 Smith BD, Soellner MB, Raines RT. Synthetic surfaces for ribonuclease adsorption. Langmuir : the Acs Journal of Surfaces and Colloids. 21: 187-90. PMID 15620301 DOI: 10.1021/La0480686  0.653
2003 Smith BD, Soellner MB, Raines RT. Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid). The Journal of Biological Chemistry. 278: 20934-8. PMID 12649287 DOI: 10.1074/Jbc.M301852200  0.707
2000 Ott CM, Smith BD, Portis AR, Spreitzer RJ. Activase region on chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase. Nonconservative substitution in the large subunit alters species specificity of protein interaction. The Journal of Biological Chemistry. 275: 26241-4. PMID 10858441 DOI: 10.1074/Jbc.M004580200  0.348
1997 Knäuper V, Smith B, López‐Otin C, Murphy G. Activation of Progelatinase B (proMMP‐9) by Active Collagenase‐3 (MMP‐13) Febs Journal. 248: 369-373. PMID 9346290 DOI: 10.1111/J.1432-1033.1997.00369.X  0.341
1997 Knäuper V, Docherty AJP, Smith B, Tschesche H, Murphy G. Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP‐8) to stability and collagenolytic activity by alanine scanning mutagenesis Febs Letters. 405: 60-64. PMID 9094424 DOI: 10.1016/S0014-5793(97)00158-0  0.346
1997 Knäuper V, Cowell S, Smith B, López-Otin C, O'Shea M, Morris H, Zardi L, Murphy G. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. The Journal of Biological Chemistry. 272: 7608-16. PMID 9065415 DOI: 10.1074/Jbc.272.12.7608  0.337
1996 Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3 Journal of Biological Chemistry. 271: 17119-17123. PMID 8663332 DOI: 10.1074/Jbc.271.29.17119  0.32
1996 Knäuper V, Will H, López-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme Journal of Biological Chemistry. 271: 17124-17131. PMID 8663255 DOI: 10.1074/Jbc.271.29.17124  0.33
1996 Knäuper V, López-Otin C, Smith B, Knight G, Murphy G. Biochemical Characterization of Human Collagenase-3 Journal of Biological Chemistry. 271: 1544-1550. PMID 8576151 DOI: 10.1074/Jbc.271.3.1544  0.337
1994 Crabbe T, Smith B, O'Connell J, Docherty A. Human progelatinase A can be activated by matrilysin Febs Letters. 345: 14-16. PMID 8194591 DOI: 10.1016/0014-5793(94)00412-9  0.336
Show low-probability matches.